StreetInsider.com News Articles

ADARx IPO raises $602.5M after underwriters exercise full option

Thu, 01 Oct 2026 16:15:13 -0400

ADARx Pharmaceuticals, Inc. (Nasdaq: ADRX) announced that underwriters fully exercised their option to purchase an additional 3,937,500 shares of common stock at $17.00 per share, closing October 1, 2026.

The exercise brings the total shares sold in the initial public offering to 30,187,500, generating approximately $513.2 million in gross proceeds before underwriting discounts, commissions, and offering expenses.

AbbVie separately purchased 5,255,542 shares at $17.00 per share in a concurrent private placement. Combined with the IPO proceeds, the total gross proceeds to ADARx reached approximately $602.5 million, before deducting underwriting discounts, placement agent fees, and other expenses.

J.P. Morgan, Morgan Stanley, TD Cowen, and

ADARx IPO raises $602.5M after underwriters exercise full option

Thu, 01 Oct 2026 16:15:13 -0400

J.P. Morgan, Morgan Stanley, TD Cowen, and

ADARx Pharmaceuticals Announces the Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares Granted in Its Initial Public Offering

Thu, 01 Oct 2026 16:15:00 -0400

SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx) (Nasdaq: ADRX), a late-stage clinical biotechnology company developing next-generation siRNA therapeutics, announced today that, in connection with its upsized initial public offering of its common stock, the underwriters have fully exercised their option to purchase an additional 3,937,500 shares of ADARx’s common stock at a price to the public of $17.00 per share. The issuance of the additional shares closed on October 1, 2026, bringing the total number of shares sold in the initial public offering to 30,187,500 shares and the aggregate gross proceeds to

ADARx Pharmaceuticals Announces the Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares Granted in Its Initial Public Offering

Thu, 01 Oct 2026 16:15:00 -0400

Adarx Pharmaceuticals allocates 55% of IPO to 10 investors

Fri, 25 Sep 2026 10:34:15 -0400

Investing.com -- Adarx Pharmaceuticals Inc. distributed approximately 55% of shares in its initial public offering to 10 institutional investors, according to a Friday report by Bloomberg.

The RNA-silencing drug developer priced its IPO at $17.00 per share for 26,250,000 shares of common stock. The San Diego-based biotechnology company expects to receive gross proceeds of approximately $446.3 million before deducting underwriting discounts, commissions, and other expenses.

The upsized offering attracted demand for around 10 times the available shares and drew orders from long-only investors and healthcare-dedicated funds, according to the report. The top 25 investors received about 95% of the shares.

Management was heavily

ADARx Pharmaceuticals indicated to open at $28, IPO priced at $17

Fri, 25 Sep 2026 10:31:23 -0400

Shares of ADARx Pharmaceuticals are indicating to open for trading at $28 on Friday, more than 60% above the company's IPO pricing of $17 per share.

ADARx Pharmaceuticals prices $446.3M IPO at $17 per share

Thu, 24 Sep 2026 19:33:24 -0400

ADARx Pharmaceuticals, Inc. priced its initial public offering of 26,250,000 shares of common stock at $17.00 per share, according to a company statement. The San Diego-based biotechnology company expects gross proceeds of approximately $446.3 million before deducting underwriting discounts, commissions, and other expenses.

The shares are expected to begin trading on the Nasdaq Global Select Market on Sept. 25, 2026, under the ticker symbol NASDAQ: ADRX. The offering is expected to close on Sept. 28, 2026, subject to customary closing conditions. Underwriters have a 30-day option to purchase up to an additional 3,937,500 shares at the public offering price.

Concurrent with the

ADARx Pharmaceuticals prices $446.3M IPO at $17 per share

Thu, 24 Sep 2026 19:33:24 -0400

Concurrent with the

ADARx Pharmaceuticals Announces Pricing of Upsized $446.3 Million Initial Public Offering

Thu, 24 Sep 2026 19:33:00 -0400

SAN DIEGO, Sept. 24, 2026 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation siRNA therapeutics, announced today the pricing of its upsized initial public offering of 26,250,000 shares of common stock at a price to the public of $17.00 per share. All of the shares of common stock are being offered by ADARx. The gross proceeds to ADARx from the offering, before deducting underwriting discounts and commissions and offering expenses payable by ADARx, are expected to be approximately $446.3 million. In addition, the underwriters have a 30-day option to purchase up

ADARx Pharmaceuticals Announces Pricing of Upsized $446.3 Million Initial Public Offering

Thu, 24 Sep 2026 19:33:00 -0400

ADARx Pharmaceuticals targets $1.74 billion valuation in US IPO

Mon, 21 Sep 2026 06:45:50 -0400

Investing.com -- ADARx Pharmaceuticals aims to achieve a valuation of up to $1.74 billion through its U.S. initial public offering, the company said on Monday.

The San Diego, California-based biotech firm plans to raise up to $371.9 million by offering 21.9 million shares at a price range of $15 to $17 per share.

AbbVie has agreed to purchase shares through a concurrent private placement, which would give it approximately a 4.9% stake in ADARx following the IPO, the company said.

The offering will be underwritten by JP Morgan, Morgan Stanley, TD Cowen, UBS Investment Bank and LifeSci Capital.

ADARx plans to list its shares

ADARx Pharmaceuticals (ADRX) files for 21.875M share IPO at $15-$17/sh

Mon, 21 Sep 2026 06:11:26 -0400

ADARx Pharmaceuticals (ADRX) filed for 21,875,000 share IPO at $15-$17 per share

ADARx Pharmaceuticals (ADRX) files for 21.875M share IPO at $15-$17/sh

Mon, 21 Sep 2026 06:11:26 -0400

ADARx Pharmaceuticals (ADRX) filed for 21,875,000 share IPO at $15-$17 per share

ADARx Pharmaceuticals (ADRX) files for Nasdaq IPO

Mon, 14 Sep 2026 17:04:29 -0400

(Updated - September 14, 2026 5:04 PM EDT)

ADARx Pharmaceuticals (ADRX) filed for a proposed Nasdaq IPO.

The company describes itself as: "We are a late-clinical stage biotechnology company focused on developing next-generation siRNA therapeutics designed to treat a broad spectrum of diseases. We are focused on advancing and expanding our pipeline of highly potent, selective and durable siRNA therapeutic candidates, including three clinical-stage programs and two advanced preclinical programs. Our goal is to control the expression of specific disease drivers with highly selective RNA targeted therapies, delivering life-changing treatments for patients with urgent unmet medical needs. Our team is united by

ADARx Pharmaceuticals (ADRX) files for Nasdaq IPO

Mon, 14 Sep 2026 17:04:29 -0400

(Updated - September 14, 2026 5:04 PM EDT)

ADARx Pharmaceuticals (ADRX) filed for a proposed Nasdaq IPO.

ADARx Pharmaceuticals (ADRX) files for Nasdaq IPO

Mon, 14 Sep 2026 17:04:29 -0400

(Updated - September 14, 2026 5:04 PM EDT)

ADARx Pharmaceuticals (ADRX) filed for a proposed Nasdaq IPO.

ADARx Pharmaceuticals files for proposed IPO

Fri, 04 Sep 2026 17:28:55 -0400

(Updated - September 4, 2026 5:28 PM EDT)

ADARx Pharmaceuticals has filed for a proposed initial public offering on the Nasdaq Global Market under the ticker symbol ADRX, according to a press release statement. The company did not disclose the timing or size of the offering.

ADARx describes itself as a late-clinical stage biotechnology company focused on developing siRNA, or small interfering RNA, therapeutics. The company said its pipeline includes three clinical-stage programs and two advanced preclinical programs targeting a range of diseases.

siRNA therapeutics work by targeting diseases at the genetic level through mRNA or RNA, without making permanent changes to a

ADARx Pharmaceuticals files for proposed IPO

Fri, 04 Sep 2026 17:28:55 -0400

(Updated - September 4, 2026 5:28 PM EDT)

siRNA therapeutics work by targeting diseases at the genetic level through mRNA or RNA, without making permanent changes to a

ADARx Pharmaceuticals files for proposed IPO

Fri, 04 Sep 2026 17:28:55 -0400

(Updated - September 4, 2026 5:28 PM EDT)

siRNA therapeutics work by targeting diseases at the genetic level through mRNA or RNA, without making permanent changes to a

ADARx Pharmaceuticals files for proposed IPO

Fri, 04 Sep 2026 17:28:55 -0400

(Updated - September 4, 2026 5:28 PM EDT)

siRNA therapeutics work by targeting diseases at the genetic level through mRNA or RNA, without making permanent changes to a